News

ArcticZymes awarded funding from the Horizon2020 programme

(Tromsø 01. April 2016) Biotec Pharmacon ASA (“Biotec”,OSE: BIOTEC) is pleased to announce that ArcticZymes, a subsidiary of Biotec Pharmacon has received EUR 460.000 over the next four years in a project funded by the European Framework Programme for Research and Innovation, Horizon 2020.

“We are excited to participate in the new granted “Virus-X” EU Consortium. It will allow ArcticZymes to expand its access to novel molecular enzymes via the bioprospecting of a wide diversity of viral genomes.”, says Jethro Holter, Managing … continue reading »

Biotec unveils new website and Facebook page for Woulgan®

(Tromsø, 31 March 2016) Biotec Pharmacon ASA (”Biotec”, OSE: BIOTEC) announced today the launch of a new website for Woulgan®, along with a dedicated product Facebook page.

– Biotec is pleased to unveil a new website focused solely on the Woulgan product. The site, along with a brand new Facebook page, will enable wound care specialists, general clinicians, as well as patients and patient interest groups to access reference materials, product information sheets and news, says Svein Lien, CEO of … continue reading »

Biotec BetaGlucans has entered into supply agreement for delivery of M-Glucan

(Tromsø 11. March 2016) Biotec Pharmacon ASA’s (OSE:BIOTEC) subsidiary Biotec BetaGlucans AS has today entered into a supplier agreement with a new feed company for deliveries of its beta-glucan product M-Glucan for use in animal health.

Deliveries under the agreement will commence from May 1st 2016 and run for 24 months. Expected revenues for the indicated period is around NOK 20 million depending on sales.

“We are very pleased to sign up new customers for our well documented animal health product as … continue reading »

Biotec Pharmacon has received “Notice of Allowance” for Woulgan gel in the US

Biotec Pharmacon ASA (OSE: BIOTEC)  has received a Notice of Allowance for its Woulgan gel in the US.

The allowed patent application has the application number US 13/989,594, title of invention: Glucan Gels. The claims cover the gel glucan product comprising SBG, a method of producing the gel glucan product and the product obtainable by this method as well as a medical composition comprising the gel glucan.

“We are very pleased with this patent as it will open up for opportunities in the … continue reading »

Biotec Pharmacon: Invitation to Q4 2015 presentation and Capital Markets Day

(Tromsø, 3 February 2016) Biotec Pharmacon ASA (”Biotec”), OSE: BIOTEC) will host a Capital Markets Day (CMD) Thursday 11 February 2016, following the Q4 presentation.

Time: 08:30 – 11:00
Location: Hotel Continental, Stortingsgaten 24/26, 0117 Oslo

Breakfast will be served prior to the presentations. For practical reasons, investors, analysts and journalists are encouraged to register via email to ir@biotec.no by 8 February 2016.

Capital Markets Day agenda
0830 – 0900      Q4 Presentation, Svein Lien, CEO
0905 – 0905      CMD Introduction, Svein Lien, CEO
0905 – … continue reading »

ArcticZymes certified according to ISO 9001:2008

ArcticZymes has received ISO 9001:2008 certification for Product development, Sales and Marketing, Manufacturing and Distribution of Enzymes for use in Molecular Biology and Diagnostics. This is an extension of previous ISO 9001:2008 certificate that only covered rSAP and COD UNG.

The certificate is valid for 3 years.